NCT02595359View on ClinicalTrials.gov

Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis

PHASE2CompletedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 20, 2018

Study Completion Date

June 20, 2018

Conditions
Endophthalmitis
Interventions
DRUG

Moxifloxacin

Moxifloxacin intracameral

Trial Locations (1)

50740600

UFPE Ophthalmology, Recife

All Listed Sponsors
lead

Universidade Federal de Pernambuco

OTHER

NCT02595359 - Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis | Biotech Hunter | Biotech Hunter